HUMPHREY RACHEL
Known title: DirectorCIK: 0001579781
Associated companies
Transaction History
| PYXS | ▼ Sell | Open Market | 13,896 | $14K | 4/21/2025 | View on chart |
| PYXS | ▼ Sell | Open Market | 200 | $194 | 4/17/2025 | View on chart |
| PYXS | ▼ Sell | Open Market | 1,400 | $1K | 4/14/2025 | View on chart |
| PYXS | ▲ Buy | Grant | 38,741 | $0 | 3/26/2024 | View on chart |
| PYXS | ▲ Buy | Grant | 58,064 | $0 | 3/24/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Pyxis Oncology Announces $282.6M Public Offering, Stock Drops
Pyxis Oncology disclosed it will price a public offering of up to $282.6 million, including common stock and warrants. The announcement was followed by a decline in the stock price in pre‑market trading. The company also ended a prior $150 million at‑the‑market offering that had not sold any shares. These moves add to the company’s ongoing effort to fund its Phase 3 development program.
Pyxis Oncology Announces $282.6M Public Offering, Stock Drops. Pyxis Oncology disclosed it will price a public offering of up to $282.6 million, including common stock and warrants. The announcement was followed by a decline in the stock price in pre‑market trading. The company also ended a prior $150 million at‑the‑market offering that had not sold any shares. These moves add to the company’s ongoing effort to fund its Phase 3 development program.